Acadia Healthcare Company Inc
NASDAQ:ACHC

Watchlist Manager
Acadia Healthcare Company Inc Logo
Acadia Healthcare Company Inc
NASDAQ:ACHC
Watchlist
Price: 13.61 USD 4.29% Market Closed
Market Cap: $1.3B

Acadia Healthcare Company Inc
Investor Relations

Acadia Healthcare Company Inc. stands as a significant pillar in the healthcare industry, specializing in providing behavioral healthcare services. Founded in 2005, the company has grown through strategic acquisitions and organic expansion to become a leading force in the mental health sector. Acadia operates a wide array of facilities, which include inpatient psychiatric hospitals, residential treatment centers, outpatient clinics, and therapeutic school-based programs. These establishments offer a range of services such as substance abuse treatment, mental health counseling, and specialized programs for various psychological disorders. By implementing evidence-based treatment methods and prioritizing patient-centered care, Acadia has effectively positioned itself to meet the increasing demand for mental health services in both the United States and internationally.

The company's revenue model is primarily driven by patient service revenues, which are largely paid through a mix of government programs like Medicare and Medicaid, private insurance, and direct patient payments. Acadia benefits from various streams of reimbursement, navigating the complexities of healthcare payment systems while ensuring access to care. As mental health awareness continues to rise, the demand for comprehensive behavioral healthcare services expands, providing Acadia with significant growth opportunities. Its strategy involves not only catering to existing needs but also anticipating future trends in the mental health landscape, maintaining its role as a crucial player in a field where quality care can drastically change lives. Through this model, Acadia Healthcare continues to achieve a critical balance of financial stability and profound societal impact.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 6, 2025
AI Summary
Q3 2025

Revenue Growth: Acadia Healthcare reported Q3 2025 revenue of $851.6 million, up 4.4% year-over-year, but revised its full-year revenue guidance downward.

EBITDA Pressure: Adjusted EBITDA for the quarter was $173 million, down from $194.3 million last year and below expectations due to lower volumes and increased bad debt.

Guidance Cut: Full-year 2025 adjusted EBITDA guidance was lowered to $650–660 million from $675–700 million, and adjusted EPS guidance was also reduced.

Capital Spending Shift: The company plans to cut 2026 capital expenditures by at least $300 million versus 2025 and expects positive adjusted free cash flow for the full year 2026.

Operational Adjustments: Acadia closed five underperforming facilities and is pausing or canceling projects that do not meet return thresholds, focusing on high-demand, high-return markets.

Payer Headwinds: Management highlighted payer-related challenges, especially in Medicaid, including tougher rate negotiations, increased denials, and shorter lengths of stay.

Legal Costs Declining: Legal and government investigation costs dropped 28% quarter-over-quarter and are expected to decline further.

Bed Expansion: The company added 908 beds YTD and expects 945–1,076 new beds in 2025, with another 500–700 beds planned for 2026.

Key Financials
Revenue
$851.6 million
Adjusted EBITDA
$173 million
Same-facility Revenue Growth
3.7%
Revenue per Patient Day (Same-facility)
up 2.3%
Patient Days (Same-facility)
up 1.3%
Adjusted EPS
$2.35–2.45
CapEx
$135.8 million in Q3; $610–630 million in 2025
Cash and Cash Equivalents
$118.7 million as of September 30, 2025
Net Leverage Ratio
3.4x
Legal and Government Investigation Expenses
$39 million in Q3
Beds Added (YTD 2025)
908 beds
Comprehensive Treatment Centers
177 CTCs in 33 states
Start-up Losses (Q3)
$13.3 million
Medicaid Supplemental Payments (2025)
High end of $30–40 million estimate
Earnings Call Recording
Other Earnings Calls

Management

Mr. Christopher Howal Hunter
CEO & Director
No Bio Available
Ms. Heather Dixon CPA
Chief Financial Officer
No Bio Available
Mr. Brian P. Farley J.D.
Executive VP, General Counsel & Secretary
No Bio Available
Mr. John S. Hollinsworth
Advisor
No Bio Available
Dr. Nasser Khan M.D.
Chief Operating Officer
No Bio Available
Ms. Laura Groschen
Chief Information Officer
No Bio Available
Ms. Gretchen Hommrich
Vice President of Investor Relations
No Bio Available
Mr. Mark Palmenter
Chief Marketing Officer
No Bio Available
Ms. Isa Diaz
Senior Vice President of Strategic Affairs
No Bio Available
Mr. Andrew Lynch
Chief Strategy Officer
No Bio Available

Contacts

Address
TENNESSEE
Franklin
6100 Tower Cir Ste 1000
Contacts